

**FMHL/SE/BM/FEB'20**

**February 3, 2020**

The General Manager  
Department of Corporate Services  
BSE Limited  
PhirozeJeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip Code: 523696

**Sub: Outcome of the Board Meeting**

Dear Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 3, 2020, *inter-alia*, considered and approved un-audited standalone and consolidated financial results of the Company for the quarter and period ended on December 31, 2019 along with limited review reports thereon;

Please find enclosed Un-audited standalone and consolidated financial results along with limited review reports for quarter and period ended on December 31, 2019, and a copy of the press release being issued in this regard.

The Board Meeting commenced at 1500 Hours and concluded at 1845 Hours.

This is for your information and records please.

Yours faithfully  
For **Fortis Malar Hospitals Limited**


**Shashank Porwal**  
**Company Secretary**

FORTIS MALAR HOSPITALS LIMITED (CIN: L8510PB1989PLC045948)  
 Regd. Office: Fortis Hospital, Sector 62, Phase - VIII, Mohali-160062  
 Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002  
 Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31-DECEMBER-2019

No.	Particulars	(Rs. in Lakhs except EPS)											
		Standalone Quarter ended			Standalone Nine Months ended			Standalone Year ended			Consolidated		
		31-Dec-2019 (Unaudited)	30-Sept-2019 (Unaudited)	31-Dec-2018 (Unaudited)	31-Dec-2019 (Unaudited)	31-Dec-2018 (Unaudited)	31-March-2019 (Audited)	31-Dec-2019 (Unaudited)	30-Sept-2019 (Unaudited)	31-Dec-2018 (Unaudited) *	31-Dec-2019 (Unaudited)	31-Dec-2018 (Unaudited) *	31-March-2019 (Audited)
1	<b>Income</b>												
	a) Revenue from operations	2,713.43	3,070.42	3,873.16	8,971.23	10,944.05	14,459.39	2,713.43	3,070.42	3,873.16	8,971.23	10,944.05	14,459.39
	b) Other income	301.68	189.23	218.94	742.48	653.03	968.44	303.82	201.97	229.68	766.66	685.15	1,011.08
	<b>Total income</b>	<b>3,015.11</b>	<b>3,259.65</b>	<b>4,092.10</b>	<b>9,713.71</b>	<b>11,597.08</b>	<b>15,427.83</b>	<b>3,017.25</b>	<b>3,272.39</b>	<b>4,102.84</b>	<b>9,737.89</b>	<b>11,629.20</b>	<b>15,470.47</b>
2	<b>Expenses</b>												
	a) Purchase of medical consumables and drugs	407.80	736.59	839.68	1,805.48	2,454.55	3,302.36	407.80	736.59	839.68	1,805.48	2,454.55	3,302.36
	b) Changes in inventories of medical consumables and drugs	3.27	1.64	(0.07)	21.19	-40.41	37.43	5.27	1.64	(0.07)	21.19	40.41	37.43
	c) Employee benefits expense	529.62	585.46	599.90	1,668.44	1,757.69	2,314.50	531.42	588.16	607.45	1,675.64	1,780.34	2,345.85
	d) Finance costs	195.08	198.06	11.61	589.98	41.44	50.90	195.08	198.06	11.61	589.98	41.44	50.90
	e) Professional charges / consultation fees to doctors	834.18	991.75	987.49	2,820.08	3,040.36	4,016.39	832.11	988.65	979.04	2,811.80	3,014.91	3,983.18
	f) Clinical establishment fees	203.49	226.06	544.77	668.09	1,594.56	2,114.99	203.49	226.06	544.77	668.09	1,594.56	2,114.99
	g) Depreciation and amortization expenses	319.96	305.21	108.59	927.38	324.17	438.31	319.96	305.20	108.59	927.38	324.17	438.31
	h) Other expenses	768.21	662.63	766.64	2,094.22	2,165.27	2,916.96	769.99	663.59	766.94	2,097.65	2,166.17	2,918.38
	<b>Total expenses</b>	<b>3,263.61</b>	<b>3,707.40</b>	<b>3,858.61</b>	<b>10,594.86</b>	<b>11,418.45</b>	<b>15,191.84</b>	<b>3,265.12</b>	<b>3,707.96</b>	<b>3,858.01</b>	<b>10,597.21</b>	<b>11,416.55</b>	<b>15,191.40</b>
3	<b>Profit/ (loss) from ordinary activities before tax (1-2)</b>	<b>(248.50)</b>	<b>(447.75)</b>	<b>233.49</b>	<b>(881.15)</b>	<b>178.63</b>	<b>235.99</b>	<b>(247.87)</b>	<b>(435.56)</b>	<b>244.83</b>	<b>(859.32)</b>	<b>212.65</b>	<b>279.07</b>
4	<b>Tax expense</b>	<b>(46.28)</b>	<b>(124.56)</b>	<b>72.94</b>	<b>(222.28)</b>	<b>50.43</b>	<b>62.32</b>	<b>(46.12)</b>	<b>(121.56)</b>	<b>75.89</b>	<b>(216.61)</b>	<b>59.27</b>	<b>73.52</b>
5	<b>Net profit/ (loss) from ordinary activities after tax (3-4)</b>	<b>(202.22)</b>	<b>(323.19)</b>	<b>160.55</b>	<b>(658.87)</b>	<b>128.20</b>	<b>173.67</b>	<b>(201.75)</b>	<b>(314.00)</b>	<b>168.94</b>	<b>(642.71)</b>	<b>153.38</b>	<b>205.55</b>
	Other comprehensive income / (loss) (net of tax) items that will not be reclassified subsequently to the statement of profit and loss												
	(a) Remeasurements of the defined benefit plans	-	43.16	(14.35)	27.42	10.88	15.41	-	43.16	(14.35)	27.42	10.88	17.03
	(b) Income tax relating to items that will not be reclassified to profit or loss	-	(12.01)	3.99	(7.63)	(3.03)	(4.29)	-	(12.01)	3.99	(7.63)	(3.03)	(4.71)
6	<b>Other comprehensive income/ (loss) (net of tax)</b>	-	<b>31.15</b>	<b>(10.36)</b>	<b>19.79</b>	<b>7.85</b>	<b>11.12</b>	-	<b>31.15</b>	<b>(10.36)</b>	<b>19.79</b>	<b>7.85</b>	<b>12.32</b>
7	<b>Total comprehensive income/ (loss) for the period /year (5+6)</b>	<b>(202.22)</b>	<b>(292.04)</b>	<b>150.19</b>	<b>(639.08)</b>	<b>136.05</b>	<b>184.79</b>	<b>(201.75)</b>	<b>(282.85)</b>	<b>158.58</b>	<b>(622.92)</b>	<b>161.24</b>	<b>217.87</b>
	Total comprehensive income/ (loss) attributable to												
	- Owners of the company	NA	NA	NA	NA	NA	NA	(201.75)	(282.85)	158.58	(622.92)	161.24	217.87
	- Non-controlling interests	NA	NA	NA	NA	NA	NA	-	-	-	-	-	-
8	Paid up equity share capital (face value Rs. 10 each)	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70	1,875.70
9	Reserves excluding revaluation reserves	NA	NA	NA	NA	NA	8,483.73	NA	NA	NA	NA	NA	8,661.91
10	<b>Earnings Per Share (EPS) based on (5) above (of Rs. 10 each)- (Not annualised in the quarters)</b>												
	- Basic	(1.08)	(1.73)	0.86	(3.51)	0.68	0.92	(1.07)	(1.67)	0.90	(3.42)	0.81	1.10
	- Diluted	(1.08)	(1.73)	0.85	(3.51)	0.68	0.92	(1.07)	(1.67)	0.90	(3.42)	0.81	1.09

\* Refer to note 1



STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31-DECEMBER-2019

Notes:

- 1 The unaudited standalone and consolidated financial results for the quarter ended 31 December 2019 and year to date ended 31 December 2019 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 3 February 2020. The above results have been subjected to limited review by the Statutory auditors of the Company. The auditors have issued an unmodified review report. Further, the consolidated financial result for the corresponding quarter ended 31 December 2018 and year to date ended 31 December 2018, as reported in these financial results have been approved by Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 3 February 2020, but have not been subjected to limited review by the Statutory auditors of the Company.
- 2 These unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The consolidated financial results includes the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Malar Stars Medicare Limited (collectively known as "Group")
- 4 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Company.
- 5 Effective 1 April 2019, the Company has adopted Ind AS 116 - Leases, with the date of initial application being 1 April 2019, using the modified retrospective approach. Accordingly, the Company has recognized a lease liability at the date of initial application, at the present value of the remaining lease payments discounted using the incremental borrowings rate at the date of initial application, recognized right-of-use asset at the date of initial application equals to the lease liability recognized and the comparatives have not been retrospectively adjusted. In the profit and loss for the current period, the lease rent which was hitherto accounted under clinical establishment expenses/other expenses in the previous periods has now been accounted as depreciation charge for the right-of-use asset and finance cost for interest accrued on lease liability. Accordingly, the profit for the current quarter and nine months period ended 31 December 2019 is lower by Rs. 72.56 lakhs and 223.06 lakhs (net of deferred tax created) respectively.
- 6 The Company had in earlier years applied to the Chennai Metropolitan Development Authority (CMDA) for regularization of certain deviations in the construction of the Hospital. During the year ended March 31, 2016, CMDA has issued an Order stating that the regularization application made by the Company has not been allowed. The Company had preferred an appeal before the Secretary to the Government of Tamil Nadu, Housing and Urban Development Authority against the said Order. On May 3, 2016 CMDA has also served a Locking & Sealing and De-occupation Notice to the Company stating that in view of CMDA's Order dated March 18, 2016 referred above, the construction at the site of the Hospital premises is unauthorized and has called upon the Company to restore the land to its original position within 30 days from the date of the Notice. The Company appealed to the High Court of Judicature at Madras and obtained a stay order on June 02, 2016 directing CMDA not to proceed further, till the matter is disposed. As directed by the Hon'ble High Court, CMDA Officials inspected the hospital premises and directed the Company to provide ramp facility for easy evacuation of patients. The Company has ramped up its fire detection and safety measures, constructed horizontal walkways and also obtained a Certificate from an independent agency on the adequacy of measures taken for fire prevention and safety. The Company, based on legal advice, believes that the above Order / Notices issued by CMDA are contestable and the same prima facie would not result in adverse impact on its operations/going concern as the Company has fair chance of success in the aforesaid Appeal / writ petition.
- 7 Figures for the prior periods / year have been reclassified/ regrouped wherever required to conform to the classification of the current period.
- 8 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.fortismalar.com)

Place: Gurgaon  
Date: 3 February 2020



By Order of the Board  
For and on behalf of Board of Directors of Fortis Malar Hospitals Limited

Daljit Singh  
Chairman

DIN No. 00138413



# BSR & Co. LLP

Chartered Accountants

KRM Tower, 1<sup>st</sup> & 2<sup>nd</sup> Floor,  
No 1, Harrington Road, Chetpet,  
Chennai - 600 031, India.

Telephone : +91 44 4608 3100  
Fax : +91 44 4608 3199

## **Limited review report on unaudited quarterly consolidated financial results and consolidated year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of **Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Malar Hospitals Limited (“the Parent”) and its subsidiary Company (the Parent and its subsidiary together referred to as “the Group”) for the quarter ended 31 December 2019 and year to date results for the period from 1 April 2019 to 31 December 2019 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31 December 2018 and corresponding period from 1 April 2018 to 31 December 2018, as reported in these financial results have been approved by the Parent’s Board of Directors, but have not been subjected to review, since the requirement of submission of quarterly consolidated financial results has become mandatory only from 1 April 2019.
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

**Limited review report on unaudited quarterly consolidated financial results and consolidated year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
**Page 2 of 2**

4. The Statement includes the results of Fortis Malar Hospitals Limited and its subsidiary Company-Malar Stars Medicare Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*for* **B S R & Co. LLP**  
*Chartered Accountants*  
Firm's Registration No. 101248W/W-100022



**Praveen Kumar Jain**  
*Partner*  
Membership No. 079893  
UDIN: 20079893AAAAAN5208

Place: Chennai  
Date: 3 February 2020

# B S R & Co. LLP

Chartered Accountants

KRM Tower, 1<sup>st</sup> & 2<sup>nd</sup> Floor,  
No 1, Harrington Road, Chetpet,  
Chennai - 600 031, India.

Telephone : +91 44 4608 3100  
Fax : +91 44 4608 3199

## **Limited review report on unaudited quarterly standalone financial results and standalone year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
Board of Directors of **Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Malar Hospitals Limited for the quarter ended 31 December 2019 and year to date results for the period from 1 April 2019 to 31 December 2019 (“the Statement”), being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

B S R & Co. LLP

**Limited review report on unaudited quarterly standalone financial results and standalone year to date financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Page 2 of 2**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

*for B S R & Co. LLP*

*Chartered Accountants*

Firm's Registration No. 101248W/W-100022



**Praveen Kumar Jain**

*Partner*

Membership No. 079893

UDIN: 20079893AAAAAM6021

Place: Chennai

Date: 3 February 2020

## **FORTIS MALAR REPORTS Q3 FY20 CONSOLIDATED REVENUE AT RS 27.13 CR OPERATING PROFIT FOR THE QUARTER AT (-) RS.0.37 CR**

**Chennai, February 3, 2020:** Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended Dec 31, 2019.

**Commenting on the results Mr. Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said,** “Fortis Malar has been doing exceptional clinical work and I thank the entire team of clinicians, nurses, paramedics and administrative staff for their contribution in enabling the hospital to be recognized as a world-class super specialty tertiary care centre. Fortis Malar has made a mark for itself by performing complex and high-end surgeries particularly in Cardiology, Neurology, Mother and Child Care, among others. This year, however, there has been a decline in the revenue numbers, primarily on account of the fall in Cardio-Thoracic & Vascular Surgery/Transplant revenue. Nevertheless, I have full faith in our team and I am confident that we shall soon put the past behind us and bounce back with greater gusto.”

### **Financial Highlights (consolidated) for the Quarter (Q3FY20)**

- Fortis Malar Hospitals reported operating revenue of Rs 27.13 Cr compared to Rs 38.73 Cr reported in the corresponding quarter of the previous year.
- Operating profit / (loss) for the quarter stood at Rs (-) 0.37 Cr compared to Rs 1.35 Cr in the corresponding quarter of previous year.
- Profit before tax stood at Rs. (-) 2.48 Cr compared to Rs. 2.45 Cr in corresponding quarter of previous year.
- Net profit for the quarter was at Rs (-) 2.02 Cr compared to Rs.1.69 Cr in corresponding quarter of previous year.
- Revenue from General Surgery and Neuro grew by 16% and 6% respectively compared to the corresponding quarter of previous year.

### **Financial Highlights – 9MFY20**

- Operating revenue for 9MFY20 at Rs 89.71 Cr compared to Rs 109.44 Cr reported in the corresponding previous period.
- Operating profit for 9MFY20 stood at Rs (-) 1.09 Cr compared to Rs (-) 1.07 Cr in the corresponding previous period.
- Profit before tax stood at Rs. (-) 8.49 Cr compared to Rs. 2.13 Cr in previous year period.
- Net profit for 9MFY20 was at Rs (-) 6.43 Cr compared to Rs. 1.53 Cr in corresponding previous period

### **Operational Highlights for the Q3FY20**

- **Fortis Malar Hospital prepares young parents for the monsoons**  
Fortis Malar Hospital in association with Happy Mom conducted an educative and interactive session at the hospital on ‘Prepare your child for the monsoons’ led by Dr. Jayashree Jayakrishnan, Lactation Consultant, Fortis Malar Hospital; Director & Founder – Happy Mom . The event prepared parents of toddlers and infants for the upcoming monsoons by informing them to keep their surroundings clean and maintain personal hygiene to avoid the spread of water led and mosquito borne diseases. An



informative step by step feeding guide was also presented for parents to ensure that their child receives optimum nutrition during this season. The session also focused on creating awareness on the developmental milestones (fine motor skills and gross motor skills) cognitive milestones, speech milestones for a child.

- **Get Your Toddlers Monsoon Ready**

Happymom in association Fortis Malar Hospital conducted an insightful and interactive session to help prepare parents of toddlers for the monsoons on 05th October 2019 between 2:00PM to 4:00PM at Fortis Malar Hospital, Auditorium. Dr Jayashree Jayakrishnan, Lactation Consultant, Fortis Malar Hospital; Director & Founder - Happymom will share beneficial tips to avoid common health issues faced by toddlers. The session will also cover a list of ideal foods to be fed to tiny tots (between 6 months to 2 year olds). The detailed session aims to educate the parents to keep track of milestones and developments of the child as well.

- **Fortis Malar hospital performs successful bilateral lung transplantation on India's youngest recipient**

A team of senior doctors from Fortis Malar Hospital successfully conducted a complex bilateral lung transplantation on 13-year-old Josephine Swetha from Tambaram, Chennai. Josephine who was diagnosed with pulmonary hypertension is the youngest patient in India to undergo bilateral lung transplant. This challenging procedure was performed by an expert team led by Dr. K R Balakrishnan, Director, Cardiac Sciences, Fortis Malar Hospital and Dr. Suresh Rao KG, Head of Department, Critical Care & Cardiac Anaesthesia, Fortis Malar Hospital.

- **Fortis Malar conducts a special session called UNMUTE YOURSELF on the occasion of World Mental Health Day**

On the occasion of World Mental Health Day, Fortis Malar Hospital conducted an enlightening session titled "UnmuteYourself" for the enthusiastic students of Patrician College of Arts And Science. The session led by Ms. Sneha George, Counselling Psychologist, Fortis Malar Hospital focused on the significance of silence and stigma attached to mental health. The session served as a platform to break the stigma attached to mental health and its related discussions.

- **Fortis Malar Hospital in collaboration with Senior Citizens Group honours renowned legends of Tamil Nadu**

Four eminent legends of Tamil Nadu were honoured with the distinguished 'The Most Admired Gandhian of Tamilnadu' award. Instituted by Senior Citizens Group of Besant Nagar (SCGOBN) and supported by Fortis Malar Hospitals, this is the first edition of the award that recognizes eminent contributions by individuals. This award was presented to the awardees at a grand ceremony at Fortis Malar Hospital to commemorate the 150th birth anniversary of Mahatma Gandhi and to spread the Gandhian values of truth, honesty, ethics and compassion.

- **Doctors at Fortis Malar performs Chennai's First futuristic Orthopaedic procedure to make 72-year-old walk**

Doctors at Fortis Malar Hospital performed futuristic orthopaedic keyhole procedure –All Autologous Cartilage Transplant (AACT) – to treat articular cartilage defects of the knee of a 72-year-old woman recently. This is the first time that this procedure has been performed successfully in Chennai to transplant the cartilage. The team of doctors was led by Dr Nand Kumar Sundaram, Senior Consultant, Trauma & Orthopaedic Surgeon, Fortis Malar Hospital.

### **About Fortis Malar Hospitals Ltd**

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynecology, Orthopedics, Gastroenterology, Neurology, Pediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

### **About Fortis Healthcare Ltd**

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 36 healthcare facilities (including projects under development), approximately 9,000 potential beds and over 410 diagnostic centers.

#### **DISCLAIMER**

*This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.*

### **FOR MORE INFORMATION PLEASE CONTACT**

Rokesh A  
PR & Communications  
Fortis Malar Hospitals Ltd  
Mobile:8667867754  
rokesh.a@fortishealthcare.com